Clinical Challenges in Breast Surgery: The Fundamentals of Cancer Immunotherapy

Immune checkpoint inhibitors have rapidly reshaped care for triple-negative breast cancer (TNBC)—but surgical teams increasingly encounter their downstream perioperative consequences. In this episode, we define immunotherapy through the lens of checkpoint biology, review the landmark evidence supporting pembrolizumab in metastatic PD‑L1–positive TNBC (KEYNOTE‑355) and curative-intent stage II–III TNBC (KEYNOTE‑522), and translate immune-related adverse events (irAEs) into practical periop recognition, triage, and timing decisions—especially for endocrine, pulmonary, hepatic, dermatologic, and GI toxicities.

Hosts:
- Rashmi Kumar, MD, PhD
Resident, University of Michigan General Surgery Residency Program
Twitter/X: @RashmiJKumar
- Melissa Pilewskie, MD
Attending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine
Twitter/X: @MPilewskie
- Stephanie Downs-Canner, MD
Attending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program
Twitter/X: @SDownsCanner

Learning Objectives:

Define immunotherapy and immune checkpoint inhibition in breast cancer

Summarize current clinical indications and pivotal evidence for pembrolizumab in TNBC

Equip perioperative clinicians to identify and manage immune-related adverse events (irAEs) or side effects of immunotherapy.

Rationale for Immunotherapy in Breast Cancer Review

Selecting Triple Negative Breast Cancer Patients for Immunotherapy: https://pubmed.ncbi.nlm.nih.gov/37714640/

Landmark Clinical Trials Discussed in this Episode

KEYNOTE-355: https://pubmed.ncbi.nlm.nih.gov/33232653/

KEYNOTE-522: https://pubmed.ncbi.nlm.nih.gov/33232642/

IMpassion130: https://pubmed.ncbi.nlm.nih.gov/30345906/

IMpassion131: https://pubmed.ncbi.nlm.nih.gov/33930478/

Assessment of Surgical Outcomes in patients receiving chemoimmunotherapy

Surgical outcomes after neoadjuvant chemoimmunotherapy in triple-negative breast cancer: https://pubmed.ncbi.nlm.nih.gov/38332314/

Immune Related Adverse Events and Management

Schneider BJ, et al. Management of immune-related adverse events: https://pubmed.ncbi.nlm.nih.gov/34724392/

Brahmer JR, et al. SITC clinical practice guideline: https://pubmed.ncbi.nlm.nih.gov/34177534/

Clinical Challenges in Hernia Surgery: Is Optimization Still Necessary for Hernia Surgery?

EP. 1047 · JUN. 25, 2026 · 34 MIN

Audio

Hernia

View episode

Clinical Challenges in Surgical Oncology: Melanoma

Audio

Clinical Challenges in Surgical Oncology: Melanoma

EP. 1043 · JUN. 11, 2026 · 35 MIN

Audio

Surgical Oncology

View episode

Clinical Challenges in Vascular Surgery: Phlegmasia in Pregnancy

Audio

Clinical Challenges in Vascular Surgery: Phlegmasia in Pregnancy

EP. 1042 · JUN. 8, 2026 · 38 MIN

Audio

Vascular

View episode

Clinical Challenges in Emergency General Surgery: C Diff - When to Pull the Operative Trigger

Audio

Clinical Challenges in Emergency General Surgery: C Diff - When to Pull the Operative Trigger

EP. 1040 · JUN. 1, 2026 · 33 MIN

Audio

Emergency General Surgery

View episode

Clinical Challenges in Vascular Surgery: Asymptomatic Carotid Artery Stenosis

Audio

Clinical Challenges in Vascular Surgery: Asymptomatic Carotid Artery Stenosis

EP. 1033 · MAY. 7, 2026 · 33 MIN

Audio

Vascular

View episode

Learning Objectives:

Define immunotherapy and immune checkpoint inhibition in breast cancer

Summarize current clinical indications and pivotal evidence for pembrolizumab in TNBC

Equip perioperative clinicians to identify and manage immune-related adverse events (irAEs) or side effects of immunotherapy.

Rationale for Immunotherapy in Breast Cancer Review

Selecting Triple Negative Breast Cancer Patients for Immunotherapy: https://pubmed.ncbi.nlm.nih.gov/37714640/

Landmark Clinical Trials Discussed in this Episode

KEYNOTE-355: https://pubmed.ncbi.nlm.nih.gov/33232653/

KEYNOTE-522: https://pubmed.ncbi.nlm.nih.gov/33232642/

IMpassion130: https://pubmed.ncbi.nlm.nih.gov/30345906/

IMpassion131: https://pubmed.ncbi.nlm.nih.gov/33930478/

Assessment of Surgical Outcomes in patients receiving chemoimmunotherapy

Surgical outcomes after neoadjuvant chemoimmunotherapy in triple-negative breast cancer: https://pubmed.ncbi.nlm.nih.gov/38332314/

Immune Related Adverse Events and Management

Schneider BJ, et al. Management of immune-related adverse events: https://pubmed.ncbi.nlm.nih.gov/34724392/

Brahmer JR, et al. SITC clinical practice guideline: https://pubmed.ncbi.nlm.nih.gov/34177534/

Clinical Challenges in Breast Surgery: The Fundamentals of Cancer Immunotherapy

Share

More from Clinical Challenges

Clinical Challenges in Hernia Surgery: Is Optimization Still Necessary for Hernia Surgery?

Clinical Challenges in Surgical Oncology: Melanoma

Clinical Challenges in Vascular Surgery: Phlegmasia in Pregnancy

Clinical Challenges in Emergency General Surgery: C Diff - When to Pull the Operative Trigger

Clinical Challenges in Vascular Surgery: Asymptomatic Carotid Artery Stenosis

Next Up

Explore Other Topics

Clinical Challenges in Breast Surgery: The Fundamentals of Cancer Immunotherapy

Share

More from Clinical Challenges

Clinical Challenges in Hernia Surgery: Is Optimization Still Necessary for Hernia Surgery?

Clinical Challenges in Surgical Oncology: Melanoma

Clinical Challenges in Vascular Surgery: Phlegmasia in Pregnancy

Clinical Challenges in Emergency General Surgery: C Diff - When to Pull the Operative Trigger

Clinical Challenges in Vascular Surgery: Asymptomatic Carotid Artery Stenosis

Next Up

Explore Other Topics